Source comparison
Thymosin Alpha-1 LL-37 Stack Protocol: Synergy Comparison
The table below compares the thymosin alpha-1 ll-37 stack protocol to alternative immune-modulating peptide stacks commonly used in research. Each combination is assessed for mechanism overlap, administration complexity, and observed synergy evidence. Thymosin
This comparison does not assign a generated winner or score.
- The table below compares the thymosin alpha-1 ll-37 stack protocol to alternative immune-modulating peptide stacks commonly used in research. Each combination is assessed for mechanism overlap, administration complexity, and observed synergy evidence.
- Thymosin Alpha-1 + LL-37
- Adaptive immune upregulation (Tα1) + innate antimicrobial defense (LL-37)
- Tα1 first, LL-37 2–3 hours later; twice weekly + 3× weekly monotherapy LL-37
- Murine sepsis models show 34% increase in neutrophil LL-37 expression with Tα1 pretreatment; enhanced bacterial clearance vs monotherapy
- Best-evidenced dual-pathway immune stack with non-overlapping receptor targets and staggered peak activity windows
- Thymosin Alpha-1 + BPC-157
- Adaptive immune modulation (Tα1) + tissue repair and angiogenesis (BPC-157)
- Can be co-administered; no timing dependency
- Limited direct synergy data; mechanisms don't overlap but also don't amplify each other
- Complementary but not synergistic; both peptides effective independently, minimal interaction
- Thymosin Alpha-1 + Thymosin Beta-4
- Adaptive immune (Tα1) + regulatory T-cell modulation and wound healing (Tβ4)
- Can be co-administered; both thymosin family but different pathways
- Both upregulate immune function but through separate signaling; no documented negative interaction
- Redundant immune modulation; limited evidence for additive benefit beyond Tα1 monotherapy
- LL-37 + KPV 5MG
- Antimicrobial (LL-37) + anti-inflammatory (KPV)
- Can be co-administered or staggered; no strict timing requirement
- KPV reduces NF-κB signaling; may dampen LL-37-induced inflammatory cytokine response in certain models
- Useful for research requiring antimicrobial activity without inflammatory cascade; not immune-enhancing
- Thymosin Alpha-1 Monotherapy
- Adaptive immune upregulation only
- Twice weekly at 1.6–3.2mg
- Extensive clinical and research data; effective for chronic viral suppression and T-cell modulation
- Simpler protocol; effective for adaptive immunity research without antimicrobial focus
- The thymosin alpha-1 ll-37 stack protocol is the only combination in this table with published evidence of direct pharmacological synergy. The mechanism of one peptide (Tα1) measurably enhances the activity of the other (LL-37) when dosed within the correct time window. Other combinations may be complementary, but they don't amplify each other's primary mechanism the way this stack does.